Systemic sclerosis & Raynaud's
Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study
Authors' conclusion
People with SSc, in aggregate, appear to be weathering the pandemic well
Study context
- Population
- People with systemic sclerosis (SSc) from the ongoing SPIN Cohort and external enrolees, from April 2020 through March 2022
- Outcome
- Trajectories of mental health symptoms: anxiety, depression, loneliness and fear of COVID-19
- Follow-up
- Through March 2022
Methodological detailsSPIN COVID-19 cohort, 28 COVID-19 assessments up to March 2022, sensitivity analysis in completers, stratified by sex, age, country and SSc subtype
- SPIN COVID-19 cohort
- 28 COVID-19 assessments up to March 2022
- Sensitivity analysis in completers
- Stratified by sex, age, country and SSc subtype
Main finding
As reported in the abstract
Mental health symptom trajectories
- Anxiety symptoms increased in early 2020 but returned to pre-COVID-19 levels by mid-2020 and remained stable through March 2022
- Depression symptoms did not initially change but were slightly lower by mid-2020 vs pre-COVID-19 and were stable through March 2022
- COVID-19 fear started high and decreased
- Loneliness did not change across the pandemic
Observational data: associations, not effects.
Further findings
Completers and subgroups (sex, age, country, SSc subtype)
- Results were similar for completers and for all subgroups
Original publication
Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study. Clin Exp Rheumatol. Published 12 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →